Program
Approximate slot length:
invited speakers: 45 min (35+10)
young scientists: 25 min (15+10)
November 04, 2024 - Drugging Undruggable Cancer Targets
| 12:00 – 13:30 | Welcome Reception: Light Lunch |
|
| Chair: | Martin Eilers (Wuerzburg, Germany) | |
| 13:30 – 13:45 | Elmar Wolf (Kiel, Germany): Welcome Note |
|
| 13:45 – 14:30 | Martin Eilers (Wuerzburg, Germany): Targeting MYC and MYC Proteins with PROTACs: what is the aim? |
|
| 14:30 – 14:55 | Short Talk Markus Vogt (Kiel, Germany):
Targeting MYC effector functions in pancreatic cancer by inhibiting the ATPase RUVBL1/2 |
|
| 14:55 – 15:40 | Coffee Break | |
| 15:40 – 16:05 | Short Talk Jennifer Jansen (Goettingen, Germany):
Temporary P53 Removal to sensitize cancer cells to chemotherapy |
|
| 16:05 – 16:30 | Short Talk Regina Wirsing (Wuerzburg, Germany):
Development of new UBA6-specific inhibitors |
|
| 16:30 – 16:45 | Rainer Engers (Neuss, Germany): Welcome Note AEK |
|
| 16:45 – 17:30 | Jan Krönke (Berlin, Germany): From Thalidomide to Targeted Therapy: The Evolution of Protein Degradation in Oncology |
|
| 19:00 | Dinner & Get Together |
November 05, 2024 - Rationale Design of PROTACs in academia and industry
| Chair: | Christian Reinhardt (Essen, Germany) | |
| 09:00 – 09:45 | Anja Giese/Philipp Cromm (Berlin, Germany):
Targeted Protein Degradation in Drug Discovery: key considerations and applications |
|
| 09:45 – 10:10 | Short Talk Nicola Berner (Freising, Germany):
Chemoproteomic mode of action analysis of protein kinase degraders |
|
| 10:10 – 10:35 | Short Talk Hannah Lenz (Frankfurt/Main, Germany):
Concept for PROTAC-mediated degradation of BRPF1 using Nano-Glo® HiBiT Lytic Detection System |
|
| 10:35-11:05 | Coffee Break | |
| 11:05 – 11:30 | Short Talk Yiliam Cruz Garcia (Kiel, Germany): AID models |
|
| 11:30 – 11:55 | Short Talk Bikash Adhikari (Munich, Germany):
Selective degradation of WDR5 |
|
| 11:55 – 12:10 | Christian Reinhardt (Essen, Germany):
Deutsche Krebshilfe |
|
| 12:10 – 13:40 | Lunch | |
| Chair: | Elmar Wolf (Kiel, Germany) | |
| 13:40 – 14:25 | Alessio Ciulli (Dundee, UK): New insights and twists on PROTAC and molecular glue degraders design and mechanism |
|
| 14:25 – 14:50 | Short Talk Katharina Schneider (Kiel, Germany):
Exploiting novel E3 ligases for cancer-specific degradation of oncogenic targets by PROTACs |
|
| 14:50 – 15:15 | Short Talk Napasorn Nilparuk (Wuerzburg, Germany):
Harnessing cancer-specific E3 ligases for the development of novel PROTACS |
|
| 15:15 – 16:00 | Coffee Break | |
| 16:00 - 16:40 | Short Talk Sebastian Urban (Essen, Germany, Johanna
Seier (Essen, Germany), Nikolas Klink (Dortmund,
Germany): PROTACs to investigate Deubiquitinases in cancer |
|
| 16:40 – 17:25 | Zoran Rankovic (London, UK): Developing orally bioavailable PROTACs |
|
| 19:00 | Poster Session with Finger Food and Drinks |
November 06, 2024 - Bringing PROTACs into Clinical Application
| Chair: | Jens Hoffmann (Berlin, Germany) | |
| 09:00 – 09:45 | Gwenn M. Hansen (San Francisco, USA):
Identifying Orally Bioavailable and CNS Penetrant Bifunctional Targeted Protein Degraders for the Treatment of Cancer |
|
| 09:45 – 10:10 | Short Talk Juliane Müller (Kiel, Germany):
Targeted protein degradation reveals a scaffolding function of Aurora-A kinase |
|
| 10:10 – 10:35 | Short Talk Lorenz Eing (Wuerzburg, Germany):
Development of novel chimeric degrader molecules targeting the Aurora-A/N-Myc complex to treat high-risk pediatric cancer |
|
| 10:35-11:05 | Coffee Break | |
| 11:05 – 11:30 | Short Talk Varun Jayeshkumar Shah
(Frankfurt/Main, Germany): Discovery of novel molecular glue degraders |
|
| 11:30 – 11:55 | Jens Hoffmann (Berlin, Germany):
Preclinical evaluation of Protacs and transition to human medicine |
|
| 11:55 – 12:40 | Vesna Vetma (Dundee, UK): Targeting cancer with PROTACs |
|
| 12:40 | Award Ceremony, Lunch & Farewell |